US Office of Technology Assessment (OTA) reports highlight paucity of cost-effectiveness data
This article was originally published in Clinica
Executive Summary
While oestrogen replacement therapy for post-menopausal women may be cost-effective, screening to determine which women will most benefit "needs to be evaluated", concludes a US Office of Technology Assessment report. Perhaps all older women should be placed on medication, suggests the congressional agency.